This antibody that depletes PMN but leaves untouched T and NK subsets significantly reduced the therapeutic effects of CCR1 and CCR5 shRNAs but inhibited tumor progression in mice treated with the scrambled shRNAs. This evidence concerns the gene CCR1 and neoplasm.